Tirzepatide (the active ingredient in Zepbound®) targets TWO hunger hormones — delivering up to 22.5% body weight loss. Get it prescribed online by a licensed physician.
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist — a breakthrough in obesity medicine that simultaneously activates two distinct metabolic pathways in the body. Developed by Eli Lilly, tirzepatide is FDA-approved as Zepbound® for chronic weight management (November 2023) and as Mounjaro® for type 2 diabetes. The dual mechanism is what sets tirzepatide apart from all previous weight loss medications on the market, including semaglutide (Ozempic®/Wegovy®).
Tirzepatide activates glucagon-like peptide-1 (GLP-1) receptors in the brain and gut, signaling satiety and slowing gastric emptying. This reduces overall caloric intake by making you feel full faster and for longer after meals.
The addition of glucose-dependent insulinotropic polypeptide (GIP) action is what makes tirzepatide uniquely powerful. GIP activation helps reduce GLP-1-related nausea, enhances fat metabolism, and appears to re-sensitize the body to GLP-1 signaling — making both pathways work better together.
Because tirzepatide engages both GIP and GLP-1 receptors, it produces meaningfully greater weight loss than GLP-1-only medications like semaglutide — as confirmed in direct head-to-head clinical trials. More pathways means more results.
In the landmark SURMOUNT-5 trial — the first ever head-to-head comparison of tirzepatide versus semaglutide — tirzepatide delivered 47% more weight loss than semaglutide 2.4mg (Wegovy®). This is a clinically significant difference and makes tirzepatide the most effective prescription weight loss therapy currently available.
Both tirzepatide and semaglutide represent a major leap forward in evidence-based obesity treatment. However, for patients seeking the maximum possible weight loss outcome, the clinical data clearly favors tirzepatide. Here's a side-by-side look at how these two medications compare.
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism of action | Dual GIP + GLP-1 | GLP-1 only |
| Max average weight loss | 22.5% | 14.9% |
| Brand name (weight loss) | Zepbound® | Wegovy® |
| Brand name (diabetes) | Mounjaro® | Ozempic® |
| FDA approved for weight loss | ✔ Yes (2023) | ✔ Yes (2021) |
| Compounded available | ✔ Yes | ✔ Yes |
| Dosing | 2.5 mg – 15 mg/week | 0.25 mg – 2.4 mg/week |
| Head-to-head winner (SURMOUNT-5) | ✔ Tirzepatide (+47% more loss) | — |
| Nausea profile | Lower (GIP reduces nausea) | Moderate |
Note: Both tirzepatide and semaglutide are excellent, well-studied medications. Individual results vary based on dose, lifestyle, and health profile. Your Truventa physician will evaluate your personal health history and recommend the best medication for you — whether that's tirzepatide, compounded semaglutide, Zepbound®, or Wegovy®.
Getting tirzepatide prescribed online through Truventa Medical is fast, affordable, and entirely virtual. You never need to leave home. Our licensed physicians operate in all 50 states.
Fill out our secure 5-minute online health questionnaire covering your medical history, current medications, and weight loss goals. No appointment necessary.
A licensed physician reviews your intake, evaluates your candidacy for tirzepatide, and — if medically appropriate — issues a legal prescription tailored to your specific needs and dose escalation schedule.
Your prescription is sent directly to a licensed, accredited pharmacy. Your tirzepatide injection supplies are shipped discreetly to your home, along with dosing instructions and access to ongoing physician check-ins.
Tirzepatide is administered as a once-weekly subcutaneous (under-the-skin) injection. To minimize gastrointestinal side effects and maximize tolerability, doses are gradually escalated over the first several months of treatment. The standard titration protocol follows a 4-week schedule at each dose level:
| Treatment Phase | Weekly Dose | Duration | Purpose |
|---|---|---|---|
| Weeks 1–4 | 2.5 mg/week | 4 weeks | Initiation — body adjustment |
| Weeks 5–8 | 5 mg/week | 4 weeks | Early weight loss begins |
| Weeks 9–12 | 7.5 mg/week | 4 weeks | Escalating appetite suppression |
| Weeks 13–16 | 10 mg/week | 4 weeks | Sustained weight reduction |
| Weeks 17–20 | 12.5 mg/week | 4 weeks | Approaching maximum efficacy |
| Week 21+ | 15 mg/week ★ Max Dose | Ongoing maintenance | Maximum weight loss & long-term management |
Important: Dosing is individualized for every patient. Your Truventa physician may adjust the titration schedule based on your personal response, tolerability, and weight loss progress. Not every patient needs to reach the maximum 15mg dose to achieve excellent results. Some patients maintain excellent weight loss at lower doses.
Tirzepatide is one of the most rigorously studied weight loss medications ever brought to market. The SURMOUNT clinical trial program enrolled thousands of participants across multiple phase 3 studies, establishing tirzepatide as a new gold standard in pharmaceutical obesity treatment.
At the 15mg max dose over 72 weeks in participants with obesity or overweight (without type 2 diabetes). Participants without lifestyle intervention averaged 2.5% with placebo.
Even in patients with type 2 diabetes — a population historically harder to treat for weight loss — tirzepatide delivered clinically remarkable results at the 15mg dose over 72 weeks.
In a direct head-to-head comparison, tirzepatide produced 22.8% weight loss vs. 15.5% for semaglutide 2.4mg — a 47% relative advantage, making it the more effective option in clinical trials.
Clinical trial results reflect average outcomes in study populations. Individual patient results will vary. Data sourced from published peer-reviewed literature and FDA prescribing information.
Truventa Medical offers access to both compounded tirzepatide (prepared by an FDA-registered 503B outsourcing facility) and brand-name Zepbound® (manufactured by Eli Lilly). Both contain the same active pharmaceutical ingredient. The right choice depends on your insurance, budget, and medical situation — your physician will help you decide.
Tirzepatide is indicated for chronic weight management in adults who meet specific clinical criteria. The following guidelines reflect standard FDA-approved indications. Your Truventa physician will review your complete health history to determine whether tirzepatide is appropriate for you.
Adults with a body mass index of 30 or higher (obesity classification) qualify for tirzepatide as a standalone criterion.
Adults with a BMI of 27 or higher plus at least one weight-related condition such as hypertension, type 2 diabetes, high cholesterol, or sleep apnea also qualify.
Tirzepatide is not recommended for patients with a personal or family history of medullary thyroid cancer, MEN 2 syndrome, pancreatitis, or certain other conditions your physician will assess.
Certain medications may interact with tirzepatide. Our physicians review your full medication list to ensure tirzepatide is safe for you to use.
A physician review is required. Not all applicants will qualify.
We believe in honest, upfront pricing with no surprise fees. Every plan includes your physician consultation, ongoing check-ins, and all necessary supplies — not just the medication.
503B pharmacy — same active ingredient
Eli Lilly manufactured — FDA-approved
Pricing shown is for self-pay patients. Insurance coverage varies. Eligible Zepbound® patients may qualify for Eli Lilly's savings program. Actual monthly cost may vary based on your prescribed dose. Includes physician consult, medication, supplies, and ongoing check-ins.